Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Starpharma Holdings Receives $4.0m R&D Tax Incentive Refund

12 Mar 2019  |  09:33:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Starpharma receives $4.0M R&D tax incentive refund

Starpharma announced that it has received a $4.0m R&D tax incentive refund which relates to the costs of research and development during the 2018 Financial Year. The refund is in respect of eligible R&D activities across its portfolio, including VivaGel and DEP programs. This amount was not included in its cash balance reported in the Company's Interim Report for the half-year ended 31 December 2018. It is highly supportive of the Australian Government's R&D tax incentive which encourages companies to engage in R&D programs that have the potential to improve global health outcomes, while generating economic benefits locally.

Please click here for full details

See more ASX300 News Announcements